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Abstract: To examine rhodopsin (Rho) functions in P23H rat, kinetics of Rho regeneration and 
dephosphorylation were investigated by spectrophotometric analysis and immunoﬂ  uorescence 
labeling method using speciﬁ  c antibodies toward phosphorylated 334Ser or 338Ser site. Rho 
dephosphorylation at both sites was extremely delayed in P23H retina as compared to normal 
ones. Kinetics of Rho regeneration was not altered between normal and P23H rats under dark 
adaptation. Next, to study the effects of several Ca2+ channel blockers on this model, retinal 
function and morphology were evaluated. Among them, nilvadipine showed a signiﬁ  cant protec-
tive effect against P23H retinal degeneration. Neurotrophic factor, ﬁ  broblast growth factor-2 
and Arc, known to suppress the apoptosis in the central nervous system, were signiﬁ  cantly 
upregulated upon administration of nilvadipine. The present study indicates that misregula-
tion of Rho phosphorylation may be involved as an important step in retinal degeneration 
of P23H and administration of nilvadipine may be a potential therapeutic agent for the retinal 
degenerations.
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Introduction
Retinitis pigmentosa (RP), a progressive hereditary retinal degeneration, is caused 
by the result of various genetic mutations (van Soest et al 1999). Among the 
most common are mutations in the rhodopsin (Rho) gene, including P23H (Dryja 
1992). The P23H Rho mutation causes autosomal dominant (ad) retinal degenera-
tion (Berson et al 1991). Retinal dysfunction due to abnormal disc morphology is 
involved in the molecular pathology causing the retinal degeneration in this mutation 
(Liu et al 1997). Impaired activation of the phototransduction cascade and recovery 
from activation are observed in human adRP patients with P23H mutation (Birch 
et al 1995), and the etiology of these mutations were studied expensively using 
animal models. P23H mice experiments demonstrated delayed photo-response 
recovery by double-ﬂ  ash measurements (Goto et al 1996). Thus, similarly to human 
adRP patients with P23H mutation, recovery from activation is also slow in the 
P23H mouse model. These observations suggest that the P23H model animal may 
be functionally impaired in the recovery state of biochemical reactions such as 
kinetics of Rho phosphorylation and dephosphorylation, binding of arrestin, and 
activities of guanylate cyclase and cGMP phosphodiesterase. Interestingly, lower 
levels of mRNA expressions of α-A crystalline and Rho kinase (RK), which are 
involved in post-Golgi processing of opsin and Rho phosphorylation, respectively, in 
Royal College Surgeons (RCS) rats (Maeda et al 2002) in which the retinal pigment 
epithelium (RPE) cell is affected (Mullen and LaVail 1976) by a mutation in the gene 
encoding the receptor tyrosine kinase Mertk (D’Cruz et al 2000; Gal et al 2000). Clinical Ophthalmology 2008:2(4) 822
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However, expressions of other photoreceptor cell speciﬁ  c 
proteins including Rho, transducin, arrestin and recoverin 
were almost comparable between RCS and control rats 
(Maeda et al 2002). Recently, we demonstrated that 
dephosphorylation of Rho were extremely delayed in 
RCS rat retinas during the dark adaptation by a newly 
developed method to analyze in vivo Rho phosphorylation 
employing imunohistochemistry with speciﬁ  c antibodies 
toward phosphorylated Rho at speciﬁ  c sites (Ohguro et al 
2003). Similarly, we also found signiﬁ  cant high levels of 
Rho phosphorylation in light-induced stress rat retinas 
(Ishikawa et al 2006) and cancer-associated retinopathy 
(CAR) model (Ohguro et al 2001). Therefore taken 
together, we hypothesized that abnormal kinetics of Rho 
phosphorylation and dephosphorylation may contribute to 
persistent misregulation of phototransduction processes in 
retinal degeneration. If this is the case, photosensitive Rho 
levels may be insufﬁ  cient in comparison to deactivated 
forms of Rho, photolyzed Rho and phosphorylated Rho, 
and to normalize this imbalance might be a candidate 
therapy for retinal degeneration. As regards this therapy, 
we speculated a possible mechanism; modulation of 
Rho phosphorylation and dephosphorylation kinetics 
by Ca2+.
Ca2+ ions may play a signiﬁ  cant role in the cell death by 
apoptosis, and is a critical factor regulating the recovery of 
the photoresponse (Nicotera and Orrenius 1992). Delayed 
recovery could therefore result from abnormal Ca2+ ion move-
ment or abnormal levels within cytosol of the photoreceptor 
cells (Koch and Stryer 1988). In fact, Rho phosphorylation 
by RK is exclusively regulated in a Ca2+-dependent man-
ner by a photoreceptor speciﬁ  c Ca2+-binding protein called 
recoverin (Kawamura 1991). Therefore, it is plausible that 
suppression of recoverin-dependent inhibition of RK by the 
lowering of intracellular Ca2+ levels by some drugs may 
be efﬁ  cient for the preservation of photoreceptor cells in 
retinal degeneration. Indeed, some types of Ca2+ channel 
blockers have been identiﬁ  ed to have preservation effects 
against retinal degeneration models (Frasson et al 1999; 
Yamazaki et al 2002). As described above, if the kinetics of 
Rho phosphorylation and dephosphorylation were impaired 
and photosensitive Rho levels were really insufﬁ  cient in 
comparison to phosphorylated Rho in P23H rat model, it 
would be of great interest to test the effects of Ca2+ channel 
blockers for therapy.
Therefore, in the present study, to gain new insights 
into the mechanism of retinal degeneration in P23H rats, 
photoreceptor functions including Rho regeneration, and Rho 
phosphorylation and dephosphorylation were systematically 
studied and the effects of several Ca2+ channel blockers were 
also investigated.
Materials and methods
All experimental procedures were designed to conform to 
both the ARVO statement for Use of Animals in Ophthalmic 
and Vision Research and our own institution’s guidelines.
Animals
Homozygous breeders of transgenic rats carrying Rho 
mutation of P23H (line 2, albino) were kindly provided 
by Prof. Matthew LaVail (University of California, San 
Francisco, CA). Heterozygous P23H rats were produced 
by mating homozygous breeders with wild-type Sprague 
Dawley (SD) rats. In the present study, 4- to 8-week-old SD 
rats (Crea, Tokyo, Japan) and heterozygous P23H rats reared 
in cyclic light conditions (12 h on/12 h off) were used.
Electroretinogram measurement
Details of preparation, recording technique and measurements 
of electroretinograms (ERG) have been described else-
where (Machida et al 2000). Under anesthesia, the rats were 
laid on its side with its head ﬁ  xed in place with surgical tape 
in an electrically shielded room for overnight dark-adaptation. 
The pupils were dilated with drops of 0.5 % tropicamide. 
ERGs were recorded with a contact electrode (Kyoto Contact 
Lens Co., Kyoto, Japan). A grounding electrode was placed on 
the ear. Responses evoked by white ﬂ  ashes (3.5 × 102 lx, 200 ms 
duration) using a Ganzfeld dome (SG-2002, Meiyo Co., Japan) 
were recorded and analyzed with PowerLab Scope version 3.7 
(ADI instruments Ltd., Japan).
Light and immunoﬂ  uorescence 
microscopy
Enucleated eyes were ﬁ  xed with methacarn (60% methanol, 
30% chloroform, 10% glacial acetic acid) overnight, dehy-
drated, and embedded in parafﬁ  n. Posterior segments of eyes 
cut from the enucleated eyes were embedded in parafﬁ  n. 
Retinal sections were cut vertically through the optic disc at 
2-μm thickness, mounted on subbed slides and dried. The 
sections were processed with hematoxylin-eosin staining 
after deparafﬁ  nization. For evaluation of photoreceptor cell 
survival, the sections including the full length of the retina 
from optic nerve head through the ora serrata were taken 
photo and rows of cell nuclei in outer nuclear layer (ONL) 
were counted at 200-μm intervals along whole horizontal 
retinal axis.Clinical Ophthalmology 2008:2(4) 823
Rho phosphorylation and dephosophorylation in rat retinal degeneration
For immunofluorescence labeling, deparaffinized 
sections were blocked with phosphate-buffered saline 
(PBS) containing 3% bovine serum albumin for an hour 
and then incubated overnight with anti-P-Rho334 antibody, 
anti-P-Rho338 antibody (1:500), anti-Arc antibody, or 
anti-FGF2 (1:200) at 4 °C. Sections were washed and 
incubated with fluorescein-isothiocyanate (FITC) or 
Cy3-conjugated antibodies to rabbit IgG (Cappel, Durham, 
NC) for an hour at room temperature. Speciﬁ  city controls 
were obtained by omitting the primary antibodies. Sections 
were observed by a ﬂ  uorescence microscope (Olympus, 
model BH-2, Tokyo, Japan) using suitable ﬁ  lters.
Drug administration
Nilvadipine and nifedipine were dissolved in a mixture of 
ethanol: polyethylene glycol 400:distilled water (2:1:7) at a 
concentration of 0.1 mg/ml, diluted twice with physiological 
saline before use, and injected intraperitoneally (1 ml/kg) 
into anesthetized rats daily for 4 weeks. Nicardipine and 
D-cis-diltiazem were dissolved in PBS at 0.25 mg/ml 
and 1 mg/ml, respectively and injected intraperitoneally 
(1 ml/kg) as above. As control for them, each vehicle 
solution was administrated as above. The concentrations of 
these drugs administrated to rats were determined by their 
concentrations of systemic oral administrations to human 
patients with hypertension for one day in our clinical practice 
(Triggle 1981).
Regenerated Rho concentration
Rho regeneration was determined by photospectrometric 
analysis as described previously (Ohguro et al 1995). Brieﬂ  y, 
rats were exposed by illumination condition (650 lux) for 
6 h and then subjected to dark adaptation. At different times 
of the dark adaptation, rats were euthanized and eyes were 
enucleated and cut into two, anterior and posterior segments. 
The posterior segments were homogenized with 10 mM 
Hepes buffer, pH 7.5, containing 10 mM dodesyl β-maltoside 
and 20 mM hydroxylamine by a glass/glass homogenizer. 
The sample was centrifuged at 20,000 × g and the spectra 
were recorded before and after complete bleaching. Rho 
concentrations were determined from difference in A500 
before and after bleaching as above by assuming ε500 to 
be 41,000 and the molecular weight to be 38,000.
Results
As shown in Figure 1, retinal degenerative P23H rat strains 
showed age-dependent thinning of retinal outer layers as 
described previously (Machida et al 2000), whereas there 
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Figure 1 Retinal function and morphology in P23H rats during their development. 
Changes in retinal morphology and function by ERG of P23H rat are demonstrated. 
Hematoxyline-eosine staining of retinal sections at 1 mm from optic disc of P23H 
rat eyes during different ages were photographed (A), and rows of ONL nuclei were 
analyzed (B) as described in Materials and methods.
Notes: Scale bar, 25 μm; Closed circle (SD rat); closed square (P23H).
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was no signiﬁ  cant difference in the morphology between 
control rats at Day 20. In the present study, to get an 
insight into which steps in the phototransduction cascade 
were affected in this strain, selected biochemical reactions 
in photoreceptor cells were evaluated, including Rho 
phosphorylation and dephosphorylation, and Rho regenera-
tion rates that represent the critical step of quenching the 
photoexcitation, and recovery phase after photoexcitation, 
respectively.Clinical Ophthalmology 2008:2(4) 824
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To assess Rho function, regeneration rate after bleach 
with constant light (650 lux) was ﬁ  rstly examined with P23H 
rats at the age of Day 20 without evidence of morphological 
retinal degeneration. Prior bleaching, the amount of Rho 
was compared and no signiﬁ  cant difference was observed 
between different genetic back grounds. When rats were 
exposed to constant light for 6 h and then kept in the dark, 
Rho was completely regenerated in 2 h in both animals 
employed in the study. Rates of Rho regeneration of P23H 
strains during dark adaptation from light bleach conditions 
were almost identical with normal strain, suggesting Rho 
regeneration was not affected (Figure 2).
Next, to evaluate quenching function of photoreceptor, 
Rho phosphorylation and dephosphorylation were assessed 
by immunohistochemical technique using speciﬁ  c antibodies 
against phosphorylated 334Ser or 338Ser, both of which 
have been identiﬁ  ed as major sites of phosphorylation in 
Rho in vivo (Ohguro et al 1995). In the control SD rat retina, 
334Ser and 338Ser antibody speciﬁ  cally recognized rod outer 
segments (ROS) of light-adapted but not of dark-adapted 
retina, and its immunopositivities were then gradually 
diminished from base to tip of ROS following dark adaptation 
as described previously (Ohguro et al 2003) (data not shown). 
The kinetics of dephosphorylation of phosphorylated 334Ser 
and 338Ser were determined by measuring the vertical 
lengths of immunoﬂ  uorescence labeled ROS during the dark 
adaptation. Dephosphorylation of 334Ser and 338 Ser went 
to completion within 4 h in SD rats. In contrast, in P23H rat 
dephosphorylation of these sites was extremely prolonged 
(Figure 3).
We next studied the effects of several Ca2+ channel 
blockers, which are candidates as drugs beneﬁ  cial for 
retinal degeneration based upon previous studies (Frasson 
et al 1999; Ohguro et al 2001; Yamazaki et al 2002; Ishi-
kawa et al 2006). Four different Ca2+ channel blockers, 
D-cis-diltiazem, nifedipine, nicardipine, and nilvadipine, 
which are used in clinical practice, and their vehicle 
solutions were systemically administrated to 4-week-old 
P23H rats daily for four weeks (n = 5 rats, 10 eyes in each 
condition), and then the retinal function and morphology 
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Figure 2 Time course of Rho regeneration during dark adaptation. Control or P23H 
rats (Day 20) were dark-adapted from regular room light (650 lux). At several time 
points, 0, 1, 2, 4, and 6 h, rats were euthanized and enucleated eyes were processed to 
direct Rho concentration analysis as described in the Materials and Methods. For one 
analysis two eyes from one rat were used. Experiments were performed in triplicate 
using fresh preparations.
Notes: Closed circle (SD rat); closed square (P23H).
Phosphorylation at 338Ser  
120 
100 
80 
60
40 
20 
0
0 
120 
100 
80 
60
40 
20 
0
10  20  30 40 50 60 70 80 90 100
0 10 20  30 40 50 60 70 80 90 100
Phosphorylatioin at 334Ser
Rho phosphorylation (%)
Dark adaptation (hours)
Figure 3 Kinetics of dephosphorylation in phosphorylated 334Ser and 338Ser in 
control and P23H rats. Four-week-old control and P23H rats were exposed to regular 
room light (650 lux) for 6 h and then were maintained under dark condition. Rho 
phosphorylation level was evaluated at three different time points (0, 1, 2, 3, 4, 6, 12, 
24, 48, 72, and 96 h, n = 3 per group), with immunoﬂ  uorescence labeling by anti-P-Rho 
antibodies. Vertical length of photoreceptor outer segment layers and that of ﬂ  uores-
cence labeling was measured at temporal points 1.0 mm apart from optic disc from 
6 different points from 3 different eyeballs and their ratios were plotted.
Notes: Data are expressed as the mean ± SD; Closed circle (SD rat); closed square 
(P23H rat).Clinical Ophthalmology 2008:2(4) 825
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were compared among these drugs. As shown in Figure 4, 
there was no signiﬁ  cant difference in rats treated with 
D-cis-diltiazem, nifedipine or nicardipine and their control 
rats; however, signiﬁ  cant preservation effects in retinal 
function by ERG and morphology (upper panel) were 
observed in P23H rats administrated with nilvadipine. 
To estimate the nilvadipine-dependent preservation effects 
against P23H retinal degenerations, retinal expressions of 
FGF2 and Arc, which were signiﬁ  cantly enhanced in nilva-
dipine-treated RCS rat as compared to the control (Sato 
et al 2003), were immunohistochemically investigated. 
As shown in Figure 4, lower panel, marked enhancement 
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Figure 4 Effects of several Ca2+ channel blockers on retinal function and morphology in P23H rats. P23H rat were treated with Ca2+ channel blockers, D-cis-diltiazem, nifedipine, 
nicaridipine nilvadipine or their vehicle solutions and thereafter retinal function by ERG and morphological analysis (upper panel) were performed. ERG measurements were 
performed in 10 eyes (5 rats) in each condition, and b-wave amplitudes of drug treated rats were compared with those of vehicle treated rats. Hematoxyline-eosine stained retinal 
sections at 1mm from optic disc of P23H rat eyes treated as above were photographed, and rows of ONL nuclei were analyzed as described in Materials and methods.
Notes: *P  0.01 (Mann-Whitney test). Nilvadipine- or vehicle-treated 4-week-old P23H rats were sacriﬁ  ced and their retinal sections were subjected to immunoﬂ  uorescence 
labeling by anti-FGF2 or anti-Arc antibodies (lower panel). Scale bar, 25 μm.
Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer, OPL, outer plexiform layer; ONL, outer nuclear layer; OS, outer segment.
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of the immunoreactivities of FGF2 and Arc was observed 
in nilvadipine-treated P23H rats in contrast to their 
controls.
Discussion
It has been hypothesized that quenching mechanisms during 
the phototransduction pathway are functionally affected in 
RCS rat, based upon the experimental evidence of several 
alterations in expressions of opsin (Nir et al 1987), and ROS 
protein phosphorylation levels (Heth and Schmidt 1992). 
Recently, to test this hypothesis, we developed speciﬁ  c 
antibodies toward Rho phosphorylated at 334Ser or 338Ser 
sites (Ohguro et al 2003), major phosphorylation sites in 
Rho in vivo (Ohguro et al 1995), and studied the kinetics 
of dephosphorylation of phosphorylated photolyzed Rho 
in living retina. During dark adaptation of normal control 
rats, dephosphorylated at 338Ser and 334Ser sites were 
completed within several hours (0–4 h). In contrast, the same 
immunoreactivities directed toward phosphorylated-338Ser 
and -334Ser sites resulted in a diminution at between 4 to 
7 days in RCS rat retinas under dark adaptation (Ohguro 
et al 2003). Such prolonged kinetics of the Rho dephos-
phorylation during dark adaptation was also evident in 
light-stress-induced retinal degeneration (Ishikawa et al 
2006), and significant enhancement of the phosphory-
lated form of Rho as well in a model of cancer-associated 
retinopathy (CAR), which is produced by intravitreous 
administration of anti-recoverin antibody to rats (Ohguro 
et al 2001). In addition, P23H rats in this study showed 
changes in Rho dephosphorylation kinetics during photo-
transduction cascade reactions. Consideration of the above 
suggests that deﬁ  cits in regulation of phototransduction 
cascade by Rho phosphorylation and dephosphorylation 
is presumably a common mechanism responsible for most 
retinal photoreceptor degeneration. In fact, this hypoth-
esis is supported by the previous observation that retinitis 
pigmentosa patients (Birch et al 1995) and mouse model 
(Goto et al 1996) with Rho mutations already known to 
show delayed photo-response recovery, suggesting that the 
quenching and adaptation process by Rho phosphorylation 
is impaired, in addition to a suggested disease mechanism 
of mislocalization of Rho within the photoreceptor cells 
(Green et al 2000). The status of Rho phosphorylation 
and dephosphorylation of the P23H rats after nilvadipine 
administration is very critical issue to prove our specu-
lation that mis-regulation of Rho phosphorylation and 
dephosphorylation kinetics is the mechanism causing retinal 
degeneration and this may be normalized by administration 
of the suitable Ca channel blocker. Nevertheless, analysis of 
Rho dephosphorylation is very difﬁ  cult at present because 
the retinal degeneration is also progressive during the drug 
administration period (4 weeks) and degenerative outer 
segments is not suitable for the proper analysis using immu-
nohistochemical assay as above. Thus, we have to develop 
a more precise and reliable assay system for evaluating Rho 
phosphorylation and dephosphorylation at real-time in vivo. 
Therefore this is our next project.
Since the reactions responsible for quenching and 
adaptation of the phototransduction are Ca2+-dependent (Koch 
and Stryer 1988), it is reasonable to speculate that Ca2+ channel 
blockers may have a potentially beneﬁ  cial effect on the retinal 
degeneration. Frasson and colleagues (1999) ﬁ  rst described the 
rescue of rod photoreceptor cells by a Ca2+ channel blocker, 
D-cis-diltiazem, in rd mouse, in which the gene encoding 
cGMP phosphodiesterase is affected. However Bush and col-
leagues (2000) claimed that D-cis-diltiazem had no effects on 
the photoreceptor degeneration in the Rho P23H rat. Therefore, 
the protective effect of Ca2+ channel blocker against retinal 
degeneration is controversial. Recently, to clarify this ambigu-
ity regarding the effect of Ca2+ channel blocker, we system-
atically studied the effects of several kinds of Ca2+ channel 
blockers, including D-cis-diltiazem, nicardipine, nilvadipine 
and nifedipine against several models with retinal degenera-
tion. From among these, only nilvadipine had a preservative 
effect on photoreceptor cells during retinal degeneration 
of RCS rat (Yamazaki et al 2002), light-stress-induced rat 
(Ishikawa et al 2006) and CAR model rat (Ohguro et al 2001), 
whereas, other Ca2+ channel blockers had no effects. Surpris-
ingly, the present study consistently showed that nilvadipine 
also had protective effects against P23H retinal degeneration. 
Among four Ca2+ channel blockers used in the present study, 
three dihydropyridine (DHP) (nilvadipine, nicaridipine, and 
nifedipine) and diltiazem, it was revealed that nilvadipine is 
a much higher hydrophobic chemical and well distributed in 
various types of tissue, including brain, after the systemic 
administration than others (Tokuma et al 1987; Suzuki et al 
1988). Thus, as to the reason why only nilvadipine was effec-
tive for the retinal degeneration we speculated the occurrence 
of preferable transmission of nilvadipine to the central nervous 
system, including retina as compared with other Ca2+ channel 
blockers. It was also revealed that nilvadipine had also a low-
voltage-activated Ca2+ channel blocking action in addition to 
the L-type high-voltage-activated Ca2+ channel blocking action 
(Ishibashi et al 1998). However, in contrast, much less effects 
on a LVA Ca2+ channel blocking action of nifedipine, nicari-
dipine and diltiazem have been reported (Akaike et al 1989). Clinical Ophthalmology 2008:2(4) 827
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Thus this may be another possibility since presence of retinal 
LVA Ca2+ channels has been reported (Guenther et al 1994).
In our previous study, to elucidate the molecular 
mechanism responsible for the drug effects of Ca2+ chan-
nel blocker nilvadipine on the retinal degeneration, we 
analyzed altered gene expression by mRNA profiling 
assay and found that neurotrophic factor, ﬁ  broblast growth 
factor-2 (FGF-2) and Arc, known to suppress the apoptosis 
in the central nervous system were remarkably up-regulated 
among 1101 genes commonly expressed in rodent in 
nilvadipine-treated RCS rat (Sato et al 2003). Thus, we 
suggested that systemic administration of nilvadipine to RCS 
rats increases the expression of endogenous FGF-2 and Arc 
in retina, and potentially have a protective effect against reti-
nal degeneration. In the present study, nilvadipine-induced 
enhancement of the endogenous FGF-2 and Arc expressions 
were also recognized in P23H model. FGFs constitute a large 
family of polypeptides that are important in the regulation 
of cell growth and differentiation and play a key role in 
oncogenesis and developmental processes including limb 
formation, mesoderm induction and neuronal development 
(Wagner 1991). Among FGFs, in vivo and in vitro studies 
have revealed that basic FGF (FGF-2) has been recognized 
as an important neuro-survival factor. Several in vitro and 
in vivo studies have revealed that FGF-2 prevented retinal 
degeneration (Faktorovich et al 1990; Steward and Worley 
2001). Arc (activity-regulated cytoskeleton-associated pro-
tein) was ﬁ  rst identiﬁ  ed as one of the immediate-early genes 
in neurons (Steward and Worley 2001). It was shown that Arc 
mRNA is constitutively expressed within the cell body, but 
is delivered into dendrites and accumulated at synapses upon 
an appropriate stimulus, such as a single electroconvulsive 
seizure (Lyford et al 1995). In addition, this speciﬁ  c local-
ization of Arc mRNA was shown to be dependent on local 
signaling through the NMDA receptor (Steward and Worley 
2001). Thus if these factors indeed cause beneﬁ  cial effects 
against retinal degenerations, nilvadipine-induced enhance-
ment of endogenous these factors is a promising candidate 
therapeutic strategy for retinal degeneration.
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